Roche's Withdraw of Tecentriq in Bladder Cancer a Positive Read for Seagen (SGEN) - Guggenheim
Tweet Send to a Friend
Guggenheim analyst Michael Schmidt reiterated a Buy rating and $170.00 price target on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
